Table 1 Summary of Descriptive Statistics for mean satisfaction with current formulation according to tablet/oral suspension users.

From: The preferences of people with amyotrophic lateral sclerosis on riluzole treatment in Europe

Variable

Tablet user (n = 72)

Oral suspension user (n = 32)

Dysphagic (n = 76)

Non dysphagic (n = 33)

All PALS (n = 109)

Satisfaction with the current formulation (Average)

 Mean ± SD

3.2 ± 1.2

3.0 ± 1.1

2.9 ± 1.2

3.7 ± 1.0

3.1 ± 1.2

 p-Value †

0.3846

0.0013

 

Satisfaction with the formulation

 Mean ± SD

3.0 ± 1.4

2.9 ± 1.4

2.8 ± 1.4

3.4 ± 1.3

3.0 ± 1.4

Satisfaction with handiness and easiness of preparing the treatment before administration

 Mean ± SD

3.2 ± 1.4

2.9 ± 1.2

2.9 ± 1.3

3.7 ± 1.3

3.1 ± 1.4

Satisfaction with easiness to self-administer

 Mean ± SD

3.1 ± 1.4

2.7 ± 1.3

2.6 ± 1.4

3.7 ± 1.3

2.9 ± 1.4

Satisfaction with package weight and size

 Mean ± SD

3.4 ± 1.4

3.6 ± 1.2

3.1 ± 1.4

4.0 ± 1.0

3.4 ± 1.3

  1. Level of satisfaction with the current formulation according to all participants surveyed (N = 109). Scale from 1 (not satisfied at all, left side) to 5 (greatly satisfied, right side). Categorical variables are summarized as percentage and absolute frequency versus the n° of non-missing observations [% (n/N)]; continuous variables are summarized as Mean, SD, n° of non-missing observations. † Nonparametric Mann–Whitney U-test. PALS: people with ALS; SD: standard deviation.
Back to article page